Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Diagnostics › Molecular Diagnostics › Medicare to Cover Castle Bio’s Cutaneous Melanoma Test

Medicare to Cover Castle Bio’s Cutaneous Melanoma Test

Oct 19, 2018
|
staff reporter

NEW YORK (GenomeWeb) – Medicare contractor Palmetto GBA on Thursday issued a final local coverage determination for Castle Biosciences' DecisionDx-Melanoma assay, a prognostic test for cutaneous melanoma that helps guide use of sentinel lymph node biopsy (SLNB).

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jul
23
Featured Webinar

Clinical Utility of Liquid Biopsy for the Detection of T790M to Guide Lung Cancer Treatment Strategy

This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.

What's Popular?

In Cancer

  1. Bladder Cancer Test From KDx Diagnostics Gets CE Mark

  2. AnchorDx Demonstrates Liquid Biopsy DNA Methylation Test for Early Cancer Detection

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.